Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

In a heartening milestone for pediatric care and collective compassion, baby Aasmika Das from West Bengal has successfully ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...

Aasmika Das, a baby from West Bengal, underwent a life-changing Zolgensma gene therapy for Spinal Muscular Atrophy Type 1, thanks to INR 8.41 crore raised by 5.29 lakh donors through Impact Guru. Her ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

The family has received ₹60 lakh so far and hopes that it will be able to collect ₹14.5 crore required for treatment ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...